Emily Leongini Featured in Interview on FDA’s Role in the Cannabis Industry
Emily notes that cannabis touches a wide variety of products traditionally regulated by FDA, including food, drugs, and dietary supplements. Yet, with only a few exceptions, FDA has largely deferred to the Drug Enforcement Administration (DEA), given marijuana’s Schedule I status. When asked about the pending application for the first plant-derived cannabinoid drug, Emily explains that, if approved by FDA, DEA would likely move the drug’s active ingredient (plant-derived cannabidiol (CBD)) from Schedule I to a lower schedule, which could potentially impact the burgeoning CBD industry.
Click here to read the full interview.